BridgeMD
CheckMate 032:CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 032
EU CTIS ID: 2024-516540-25-00
What this study is testing
To investigate the safety and efficacy of Nivolumab as a single agent or in combination with Ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), and small cell lung cancer (SCLC), Bladder Cancer (BC) and Ovarian Cancer (OC).
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types: Triple Negative Breast Cancer
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Gastric Cancer
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Pancreatic Cancer
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Small Cell Lung Cancer
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Ovarian Carcinoma
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Bladder Cancer
You likely can't join if
- Active brain metastases or leptomeningeal metastases
- Subjects with active, known or suspected autoimmune disease
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment
- Prior therapy with experimental anti-tumor vaccines; any T cell costimulation or checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti- PD-L2, anti-CD137, or anti-CTLA-4 antibody, including ipilimumab; or other medicines specifically targeting T cell is also prohibited
See the full eligibility criteria
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types: Triple Negative Breast Cancer
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Gastric Cancer
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Pancreatic Cancer
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Small Cell Lung Cancer
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Ovarian Carcinoma
- Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types:Bladder Cancer
- Subjects must have measurable disease
- ECOG of 0 or 1.
- Active brain metastases or leptomeningeal metastases
- Subjects with active, known or suspected autoimmune disease
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment
- Prior therapy with experimental anti-tumor vaccines; any T cell costimulation or checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti- PD-L2, anti-CD137, or anti-CTLA-4 antibody, including ipilimumab; or other medicines specifically targeting T cell is also prohibited
The study team makes the final eligibility decision.
Where it's taking place
- United States
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.